[Clinical experiences with depot neuroleptics].
Starting out from an assessment of the course of the disease in the case of 27 patients with acute or sub-acute schizophrenia, and 9 suffering from a paraphrenia and 6 patients with paranoic atypical psychoses, an attitude was established with regard to the therapeutic effectiveness of Fluphenazin-Dekanoat, Fluphenazin-Oenanthat and Flupenathixol-Dekanoat. No important distinctions between the combinations appeared. Long-term treatment with depot neuroleptica proved itself a suitable and valuable addition to anti-psychotic therapy. In the case of several patients uninterrupted remissions lasting over 3 years were achieved.
D003692:Delayed-Action Preparations; D003865:Major Depressive Disorder / Q000188:drug therapy; D005260:Female; D005475:Flupenthixol / Q000008:administration & dosage*; D005476:Fluphenazine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy; D013892:Thioxanthenes / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D013892:Thioxanthenes; D005475:Flupenthixol; D005476:Fluphenazine
Klinische Erfahrungen mit Depot-Neuroleptika.